Opus Genetics stockholders elected nine directors, ratified auditor, approved say-on-pay, and increased authorized common stock from 125M to 250M shares.
Key takeaways
All nine director nominees were elected with strong support, each receiving over 33.8M votes for.
Stockholders ratified Ernst & Young as independent auditor for fiscal 2026 with 46.8M votes for.
Say-on-pay proposal passed with 34.9M votes for, indicating shareholder approval of executive compensation.
Authorized common stock increased from 125M to 250M shares, approved by 45.4M votes for.
Broker non-votes were 12.0M for director elections and say-on-pay, reflecting significant unvoted shares.